Monitoring the bioenergetics of cardiac allograft rejection using in vivo P-31 nuclear magnetic resonance spectroscopy

Abstract

Monitoring human cardiac allograft rejection is currently accomplished by endomyocardial biopsy. Available noninvasive methods for identifying rejection have lacked the necessary sensitivity or specificity, or both, for routine clinical application. In vivo phosphorus-31 (P-31) nuclear magnetic resonance (NMR) spectroscopy has been used for monitoring phosphorus metabolism in both animal models and humans. In the present study this technique was employed as a noninvasive means to assess the bioenergetic processes that occur during cardiac allograft rejection in a rat model. Brown Norway rat hearts were transplanted subcutaneously into the anterior region of the neck of Lewis rat recipients (allografts). Control isografts employed Lewis donors and recipients. Phosphocreatine to inorganic phosphate (PCr/Pi), phosphocreatine to beta-adenosine triphosphate (PCr/ATP beta), beta-adenosine triphosphate to inorganic phosphate (ATP beta/Pi) ratios and pH of the transplanted hearts were monitored using surface coil P-31 NMR spectroscopy (at 4.7 tesla) daily for 7 days. To allow recovery from the compromise induced by the surgical procedure, the measurements obtained on day 2 were taken as a baseline. PCr/Pi was unchanged or increased in the isografts but decreased continually in allografts, with the difference becoming significant by day 4 when compared with levels in day 2 allografts (p less than 0.005) and by day 3 when compared with levels in the isograft group (p less than 0.05). PCr/ATP beta in isografts did not change throughout the study; however, allografts demonstrated a significant decrease as early as day 3 (p less than 0.01), although a significant difference between isografts and allografts did not become manifest until day 4 (p less than 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)

Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report?

“…377 Taken together, these results suggest that CMR spectroscopy can provide metabolic evidence for myocardial viability. 365 In early cardiac allograft rejection, decreased PCr/ATP ratios are seen, 378,379 although this must be distinguished from transient reductions early after transplantation that might occur on the basis of transient allograft ischaemia. In LV hypertrophy, the PCr/ATP ratio is generally normal, 380 but reductions are seen in hypertrophic cardiomyopathy.…”

Clinical Indications for Cardiovascular Magnetic Resonance (CMR): Consensus Panel Report #

“…Taken together, these results suggest that CMR spectroscopy can provide metabolic evidence for myocardial viability (Bottomley and Weiss, 1998). In early cardiac allograft rejection, decreased PCr/ATP ratios are seen (Canby et al, 1987;Fraser et al, 1990), although this must be distinguished from transient reductions early after transplantation that might occur on the basis of transient allograft ischaemia. In LV hypertrophy, the PCr/ATP ratio is generally normal (Pluim et al, 1996), but reductions are seen in hypertrophic cardiomyopathy (Jung et al, 1998;Rajagopalan et al, 1987).…”

The History of Cardiovascular Magnetic Resonance

“…Canby et al (14) were responsible for a study published in the Journal of the American College of Cardiology in which they demonstrated that the 31 P NMR spectroscopy-determined phosphocreatine/adenosine triphosphate ratio was inversely related to the severity of histologically demonstrated cardiac allograft rejection in a rat model. This relationship suggested that in vivo 31 P NMR spectroscopy might be useful for detecting and assessing the severity of cardiac rejection.…”